Hematopoietic cells as sources for patient-specific iPSCs and disease modeling

Zhaohui Ye, Cyndi F. Liu, Yoon Young Jang

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


In addition to being an attractive source for cell replacement therapy human induced pluripotent stem cells (iPSCs) also have great potential for disease modeling and drug development. During the recent several years cell reprogramming technologies have evolved to generate virus-free and integration-free human iPSCs from easily accessible sources such as patient skin fibroblasts and peripheral blood samples. Hematopoietic cells from umbilical cord blood banks and Epstein Barr virus (EBV) immortalized B lymphocyte repositories represent alternative sources for human genetic materials of diverse backgrounds. Ability to reprogram these banked blood cells to pluripotency and differentiate them into a variety of specialized and functional cell types provides valuable tools for studying underlying mechanisms of a broad range of diseases including rare inherited disorders. Here we describe the recent advances in generating disease specific human iPSCs from these different types of hematopoietic cells and their potential applications in disease modeling and regenerative medicine.

Original languageEnglish (US)
Pages (from-to)2840-2844
Number of pages5
JournalCell Cycle
Issue number17
StatePublished - Sep 1 2011
Externally publishedYes


  • B lymphocytes
  • Blood
  • Disease modeling
  • Drug testing
  • Hematopoietic differentiation
  • Hepatic differentiation
  • Induced pluripotent stem cells (iPSCs)

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Hematopoietic cells as sources for patient-specific iPSCs and disease modeling'. Together they form a unique fingerprint.

Cite this